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Abstract Liver cirrhosis in Mexico is one of the most important causes of death in persons
between the ages of 25 and 50 years. One of the reasons for therapeutic failure is the lack of
knowledge about the molecular mechanisms that cause liver disorder and make it irreversible.
One of its prevalent anatomical characteristics is an excessive deposition of ﬁbrous tissue that
takes different forms depending on etiology and disease stage.
Liver biopsy, traditionally regarded as the gold standard of ﬁbrosis staging, has been brought
into question over the past decade, resulting in the proposal for developing non-invasive tech-
nologies based on different, but complementary, approaches: a biological one that takes the
serum levels of products arising from the ﬁbrosis into account, and a more physical one that
evaluates scarring of the liver by methods such as ultrasound and magnetic resonance elastog-
raphy; some of the methods were originally studied and validated in patients with hepatitis
C.
There is great interest in determining non-invasive markers for the diagnosis of liver ﬁbrosis,
since at present there is no panel or parameter efﬁcient and reliable enough for diagnostic use.
In this paper, we describe the biomarkers that are currently being used for studying liver
ﬁbrosis in humans, their advantages and disadvantages, as well as the implementation of new-
generation technologies and the evaluation of their possible use in the diagnosis of ﬁbrosis.
© 2013 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All
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Resumen La cirrosis hepática en México es una de las principales causas de muerte en sujetos
entre los 25 y los 50 an˜os de edad. Una de las principales razones del fracaso terapéutico es el
desconocimiento de los mecanismos moleculares que producen el trastorno hepático y lo hacen
irreversible. Entre sus características anatómicas prevalece un depósito excesivo de tejido
ﬁbroso que adopta diferentes formas, dependiendo de la etiología y etapa de la enfermedad.
La biopsia hepática, considerada tradicionalmente como la referencia estándar para estad-
iﬁcar la ﬁbrosis, ha sido muy cuestionada en la última década, por lo que se ha propuesto el
desarrollo de tecnologías no invasivas basadas en enfoques distintos pero complementarios:
uno biológico que considera los niveles séricos de los productos procedentes de la ﬁbrosis y
otro físico que evalúa la cicatrización del órgano por métodos tales como, el ultrasonido, la
resonancia magnética y la elastografía, algunos de ellos, estudiados y validados inicialmente
en pacientes con hepatitis C.
Existe la necesidad de establecer marcadores hepatoespecíﬁcos no invasivos para el diag-
nóstico de ﬁbrosis hepática, ya que actualmente no se cuenta con un parámetro o panel que
cumpla con los criterios de eﬁcacia y conﬁabilidad, requeridos para su uso diagnóstico.
En este trabajo se describen los biomarcadores empleados actualmente para el estudio de
la ﬁbrosis hepática en humanos, incluyendo sus ventajas y desventajas y la implementación
de tecnologías de nueva generación, y la evaluación de las posibilidades de su empleo para el
diagnóstico.
© 2013 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A.
Todos los derechos reservados.
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Lhe process of liver ﬁbrosis
he liver has the unique role of being the metabolic center
f the body. Its average weight in adults is approximately
,400± 270 g, with no signiﬁcant difference related to sex.
t is made up of 5 different types of cells that occupy close
o 80% of its volume. The remaining 20% corresponds to the
xtracellular spaces and components of the extracellular
atrix.1
Fibrosis is a common response of the liver to chronic
esion produced by a variety of aggressions that include
etabolic diseases, viral infections, alcohol abuse, drug
buse, and autoimmune attack targeting hepatocytes and
ile ducts; congenital abnormalities are also a cause.
In the space of Disse of the normal liver, an organized
roup of proteins known as the extracellular matrix (ECM)
an be observed in direct contact with the basal lamina
low-density material similar to the «basal membrane» that
s formed by type IV collagen together with laminin and
ntactin along the sinusoidal wall).2 It makes up about
.5% of the total weight of the liver and is the support
or the parenchymatous cells. In addition to reinforcing the
rgan’s architecture, the ECM makes the interchange of
olecules among hepatocytes possible, taking place in a
emi-continuous ﬂow due to its non-ﬁbrillar composition.
his is essential for the maintenance of the differentiated
unctions of all the cells residing in the liver.
In the ﬁbrotic liver, the components of the ECM are similar
o those present in the normal liver (collagen and others),
ith the exception that they are quantitatively enlarged due
o the development of the ﬁbrosis.
The normal structure of the matrix in the subendothelial
pace is transformed into an interstitial matrix with a high
F
tontent of ﬁbrillar collagen, product of the paracrine acti-
ation of the hepatic stellate cells, induced by the Kupffer
ells, with the consequent overexpression and redistribu-
ion of the relative quantities of the ECM proteins. These
uantities are initially deposited in the portal tract and/or
entral vein, leading to the development of ﬁbrous connec-
ions between the vascular structures and followed by the
oss of the fenestrated nature of the sinusoidal endothelium
capillarization), as well as the microvilli of the hepatocytes.
his not only has an inﬂuence on ECM expansion, but also on
he interruption of the normal vascularization of the hepatic
obe, which contributes to the deterioration of the organ’s
unction.3
These changes illustrate the primary role of the ECM in
he liver, not only as a frame for its architecture, but also
s a continuous network between the cells that makes their
onstant interchange of signals, through its own receptors,
ossible.2 Fibrosis, in itself, is an important biologic event, a
roduct of the imbalance between the synthesis and degra-
ation of the ECM molecules. When associated with other
rocesses of the liver, it promotes the long-term develop-
ent of cirrhosis, which in the absence of opportune and
dequate treatment, usually leads to death.
Cirrhosis is the second cause of death at the national level
n productive-age individuals in Mexico. This has an impor-
ant impact on public health, as well as on the economy,
mplying signiﬁcant expense resulting from hospitalization,
reatment, and absenteeism in the workplace.4
iver biopsyor the last 50 years, liver biopsy has been considered
he criterion standard for classifying ﬁbrosis because it has
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Table 1 Advantages and disadvantages of liver biopsy.
Advantages Disadvantages
Diagnostic criterion
standard
Conﬁrmed diagnostic value Highly invasive test
Etiologic suggestion
Differential diagnosis The potential
complications include
death
Grade and stage evaluation
Therapeutic decision Signiﬁcant sampling
error
(eligibility) High cost
Treatment evaluation Inter-observer variation
(effectiveness)
Follow-up comparison of
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enabled physicians to obtain diagnostic information not only
about the ﬁbrosis, but also other damaging processes such
as necrosis, inﬂammation, steatosis, and copper and iron
deposits, among others.5
Today the Knodell, Ishak, and Metavir scoring systems are
the most widely used for evaluating liver biopsy.
Because the conventional biopsy observation reports did
not provide clear evaluation criteria that were convincing
and conclusive for their statistical analysis, Knodell and his
colleagues established the construction of a «histology activ-
ity index» (HAI).5
The Knodell method began to be utilized in 1981 with
the publication of a document that reported on a histologic
procedure developed to quantitatively evaluate alterations
produced by chronic hepatitis that included portal inﬂam-
mation, necrosis, periportal activity, lobular necrosis, and
ﬁbrosis. It consists of 4 individually assigned numbers that
then make up a single score. The ﬁrst component (in peri-
portal and/or bridging necrosis) is evaluated on a 0-10 scale.
The next 2 components (intralobular degeneration and por-
tal inﬂammation) are scored on a 0-4 scale. The combination
of these 3 markers indicates the quantity of inﬂammation
in the liver. The fourth component indicates the quantity
of scarring in the liver and is scored as: F0 (no scarring),
F1 (portal ﬁbrosis without septa), F3 (numerous septa with-
out cirrhosis), and F4 (cirrhosis or advanced scarring in the
liver).5
The Metavir scoring system has been specially designed
for evaluating liver status in persons infected with hepati-
tis C virus (HCV). The index includes the sum of the scores
assigned to the grade of inﬂammatory activity observed in
the sample (0-4, in which 0 is no activity and 3 or 4 is
severe activity), in addition to the staging score that rep-
resents the quantity of ﬁbrosis: 0 (no scarring), 1 (minimal
scarring), 2 (scarring has occurred and extends beyond the
areas containing blood vessels), 3 (bridges of ﬁbrosis that
are extended to and connected with other ﬁbrotic areas),
and 4 (cirrhosis).6
The American Association for the Study of Liver Dis-
eases (AASLD) recommends that «in order for a biopsy to
be considered appropriate, it should be taken with a 16
caliber needle, be 2-3 cm in length, and contain at least
11 complete portal tracts that enable adequate histologic
classiﬁcation of the parenchyma». However, few percuta-
neous samples meet these criteria in clinical practice, as
shown in a study by Regev et al. published in 2002. They
based their analysis on samples of patients with chronic
hepatitis C taken from the left and right hepatic lobes and
determined that biopsy had a high rate of inter-individual
sampling error. They demonstrated histologic grading and
staging differences (33.1%) in a large proportion of them,
but with uncommon discrepancies in more than one stage or
grade.7 This variability increased up to 60.2% in small biopsy
samples (1.5 cm) and to 86.6% in those of 1 cm (p < 0.001),8
with a mean difference of 2.4± 2.1 for the necroinﬂam-
matory activity and 0.6± 0.9 for ﬁbrosis, with an r = 0.53,
p < 0.01 and r = 0.62, p < 0.0001, respectively.9 Other studies
have demonstrated a 30% disagreement in the histopatho-
logic staging in relation to the analysis of biopsies taken from
the right and left hepatic lobes of patients with nonalco-
holic fatty liver disease. Obtaining a sample of adequate size
(> 1 cm in length with > 10 portal tracts)10 greatly reduces
p
n
atreated and untreated
patients
ampling error, considering that around 1/50,000 of the
epatic mass is retrieved.11 The article by Regev et al. may
ot be one of the most outstanding, but it is one of the
ost cited in recent reviews related to biomarkers.7 They
oint out the same disadvantage of biopsy, and the authors
lso coincide on the problem of sampling variability, which
hould be taken into account when making decisions as to
atient treatment and outcome.
Other disadvantages, such as its invasive character, poor
ample quality, and tissue size (variation coefﬁcient of 45-
5%) make biopsy non-reproducible in relation to length.11
urthermore, it is a histologic evaluation that strictly
epends on the experience of the pathologist (observer
rror).
The risks associated with obtaining a liver biopsy range
rom pain (84%) and hypotension, which are the most fre-
uent, to peritoneal bleeding (0.5%) and damage to the
iliary system as the most serious complications. Never-
heless, the level of morbidity and mortality is signiﬁcantly
ow (0.09-0.12%),12--15 sustaining the ethical considerations
nvolved in its performance, which prevent the taking of
ultiple biopsies from the same patient. Finally, these
esults frequently tend to be representative in relatively
dvanced disease.16,17 The pros and cons are summarized
n Table 1.
epatic ﬁbrosis biomarkers
n recent years, there has been increasing interest in iden-
ifying and describing hepatic ﬁbrosis through the use of
oninvasive markers.18 Fibrosis can be determined in 2 forms
noninvasive); one is based on a biologic approximation
quantiﬁcation of markers in serum) and the other is a phys-
cal approximation (measuring liver stiffness); ultimately,
he 2 are complementary.
Hardness is a characteristic property of the hepatic
arenchyma, whereas serum markers could indicate, albeit
ot strictly, an association with the stage of ﬁbrosis.19
Hepatic ﬁbrosis markers offer an attractive and afford-
ble alternative to both the patient and physician.
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Table 2 Biomarkers for liver ﬁbrosis.
Indirect markers
Simple liver function
tests
Aminotransferases (ALT,
AST), -glutamyl
transferase (GGT),
bilirubin, albumin
Hematologic variables Platelet count and
prothrombin times
Others Glucose, insulin,
apolipoprotein, cholesterol,
haptoglobin
Direct markers
Collagen, ECM
molecules and
enzymes
Procollagen N-terminal
peptide, hyaluronic acid,
type IV collagen, laminin,
ﬁbronectin, YKL-40,TIMP-1,
TIMP-2, MMP-2, MMP-9
Cytokines TGF, TNF, angiotensin-II
Proteomic markers Galectina-3 binding protein
(G3BP),
microﬁbril-associated
protein 4 (MFAP-4),
tropomyosin
Genetic markers SNP of AZIN1, TLR4, TRPM5,
AQP2, STXBP5L
AQP2: aquaporin 2; AZIN1: ornithine decarboxylase antizyme
inhibitor; STXBP5L: syntaxin-binding protein 5-like; TLR4: Toll-
like receptor 4; TRPM5: long transient receptor potential
channel 5.
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hypersplenism, myelosuppression from HCV, reduced throm-90
part from being noninvasive, there are practically no
omplications, sampling errors are few or null, and they
ave the advantage that the measurements can be done
epeatedly, thus enabling dynamic disease control. In other
ords, the fact that the measurements can be carried out
epeatedly without affecting the status of the liver (which is
ot always possible with biopsy) allows the disease progres-
ion or regression to be supervised as part of the follow-up,
hether in relation to the natural history of the hepatic
isease or as the result of treatment regimens.20
The diagnostic value of hepatic ﬁbrosis markers has been
xplored in numerous studies.
Depending on the clinical and research necessities, the
deal marker should have all of the following characteristics:
High sensitivity and speciﬁcity that enable the identiﬁca-
tion of different stages of ﬁbrosis.
Availability, safety, affordability, and reproducibility.
The capacity to differentiate ﬁbrosis from other hepatic
inﬂammatory disorders, that is to say, avoiding false posi-
tives.
Even though there is no ideal ﬁbrosis marker, various
olecules or algorithms have been identiﬁed as useful indi-
ators, when they are managed in combination.21 Some of
he new noninvasive methods have been evaluated through
he area under the curve (AUROC) analysis, using biopsy
s a reference. Nevertheless, only a few markers show an
UROC> 90, allowing them to be regarded as noninvasive
arkers of choice.
Serum biomarkers have been evaluated mainly in ref-
rence to their capacity to determine the stage of the
brosis. Two types have been proposed: direct biomarkers
hat reﬂect the deposit or elimination of the ECM in the
iver; and indirect biomarkers, that include the molecules
eleased into the blood, induced by the inﬂammation, syn-
hetized, and regulated or excreted by the organ, as a
roduct of the commonly altered processes that are a con-
equence of hepatic function deterioration.22
The direct markers presently encompass the different
ragments of the ECM components produced by the hepatic
tellate cells and other liver cells during the remodeling
rocess of the hepatic matrix;23 these include glycoproteins
uch as hyaluronic acid (HA), laminin and YKL-40, collagens
pro-collagen III and type IV collagen), and matrix metallo-
roteases and their inhibitors (TIMPs) (Table 2).
The so-called indirect markers are determined in routine
aboratory tests such as prothrombin times, platelet counts,
nd transaminase determination (alanine aminotransferase
ALT] and aspartate aminotransferase [AST]) that indicate
epatic alteration.
The most outstanding or novel markers are described
elow.
spartate aminotransferase and alanine
minotransferasehese are hepatic enzymes excreted into the bloodstream by
amaged hepatocytes. The predictive value of the AST/ALT
atio has been validated in nonalcoholic liver disease,
b
p
r
cModiﬁed from Adams et al.36
hronic viral hepatitis, primary sclerosing cholangitis, and
rimary biliary cirrhosis.24
In some forms of acute and chronic hepatitis and/or
teatosis this ratio is ≤ 1, whereas in alcoholic hepatitis an
ST/ALT ratio is often > 2. While these proportions are only
uggestive of certain hepatic etiologies, there is a superpo-
ition between the groups that exclusively depend on the
ST/ALT ratio, for example when diagnosing patients with
epatitis C with alcohol abuse. Levels of ALT and AST can
lso be elevated, although to a lesser degree, due to mus-
le, kidney, and cardiac problems.25,26 Although this ratio is
ot signiﬁcant for detecting ﬁbrosis, it has been reported
n cirrhotic patients infected with HCV that an AST/ALT
atio ≥ 1 with sensitivity and speciﬁcity values of 81.3% and
5.3%, respectively, during one year of follow-up after cir-
hosis diagnosis, combined with a platelet count, can reach
ositive predictive values of up to 100%.23,27
latelet count
hrombocytopenia is a valuable marker for advanced
iver diseases and can be related to mechanisms such asopoietin production, and the development of autoimmune
rocesses. Nevertheless, the joint evaluation of the AST/ALT
atio and platelet count (PLT) has high diagnostic value for
irrhosis (70-90%).27
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Prothrombin time
Prothrombin time (PT) is an index that reﬂects the liver’s
ability to synthesize and therefore is one of the initial indi-
cators of cirrhosis. In a retrospective study conducted on
252 patients infected with HCV, the combination of PT,
PLT, and the AST/ALT ratio was predictive of cirrhosis.27 In
another study carried out on 518 patients with chronic liver
disease, the PTs were correlated with the histologic ﬁbro-
sis score (r = --0.70, p < 0.0001), and a prothrombin index
of < 80% and < 70% was found to be diagnostic for severe
ﬁbrosis or cirrhosis, respectively, with a 95% probability.28
Another group reported that PT correlated with the pres-
ence and size of esophageal varices.29 PT is a component of
different indices.
Procollagen type I carboxy-terminal peptide and
procollagen type III amino-terminal peptide
Type I and type III collagens (ﬁbril formers) are the most
abundant in the healthy human liver. In its mature form,
collagen integrates into the ECM. During ﬁbrogenesis, the
levels of type I collagen can increase up to 8-fold and the
I/III ratio also changes, from 1:1 in the healthy liver to 1:2
in the cirrhotic liver.16
The procollagen type III amino-terminal peptide (PIIINP)
is an important component of connective tissue; its rela-
tive concentration in the basal membrane is greater during
hepatic ﬁbrogenesis due to an increase in its serum lev-
els. Its determination for clinical use is limited because
of its low sensitivity and speciﬁcity (78% and 81%, respec-
tively). In acute hepatitis, PIIINP levels correlate with the
aminotransferase levels, reﬂecting the grade of ﬁbrosis.
Unfortunately, it is not speciﬁc, given that it is also elevated
in acromegaly, pulmonary ﬁbrosis, chronic pancreatitis, and
rheumatic diseases.16,19
Procollagen type I carboxy-terminal peptide (PICP) serum
levels in patients with mild chronic infection from HCV are
not differentiated from those detected in healthy individ-
uals, increasing in only 50% of the patients with advanced or
moderate ﬁbrosis and also in those patients with liver cir-
rhosis; therefore the potential detection of all the cases of
ﬁbrosis is not possible through its determination in serum.
Because there is no correlation between serum PICP and
PIIINP levels based on their determination in serum, the
combined use of both molecules is not reliable for estab-
lishing the grade of ﬁbrosis.30
Type IV collagen
Type IV collagen is an essential component of the hepatic
ECM. Unlike the type I and type III collagens that are
processed through proteolysis, this molecule is deposited
intact in the matrix, and its presence in serum directly
reﬂects its degradation. Thus, in practice, the assays for
detecting type IV collagen fragments in serum (NC1 and
PIVNP) are more frequently used. They have a positive cor-
relation with the grade of liver ﬁbrosis in patients with
chronic viral hepatitis and alcoholic liver disease, function-
ing as sensitive indicators for the presence of cirrhosis in
hemochromatosis. In hepatitis C, the cut-off point for stage
F
i
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2 diagnosis was established at 110 ng/mL and at 130 ng/mL
or predicting stage F3.23,31 The combination of this marker
nd PIIINP resulted in a sensitivity and speciﬁcity of 88%.19
ransforming growth factor-1
ransforming growth factor-1 (TGF-1) is a pleiotropic
ytokine involved in tissue growth regulation, differenti-
tion, ECM production, and the immune response. Three
soforms of this cytokine (1, 2, and 3) have been iden-
iﬁed, but only 1 has been linked to liver ﬁbrogenesis.
GF-1 is commonly known as a central component of ﬁbro-
enic response in wounds and an over-regulator of different
iseases. The correlation between TGF-1 levels and ﬁbrosis
rogression is widely accepted.21,32
yaluronic acid
yaluronic acid (HA) is a glycosaminoglycan component of
he ECM synthesized by the hepatic stellate cells. Under
ormal circumstances the liver sinusoidal endothelial cells
LSECs) are the structures that directly intervene in its
ptake and degradation. High HA levels may be due to
ts reduced elimination or increased production; they have
een detected in the serum of patients with liver dis-
ases of different etiologies, and particularly in those with
irrhosis.23 In a study conducted on patients with nonalco-
olic fatty liver disease, HA was selected as the best ﬁbrosis
arker, with an AUROC of 0.97 and a speciﬁcity and sensitiv-
ty of 88-95% and 86-100%, respectively, for this group.19,33
owever, its positive predictive value has been reported as
ower (61%) than the negative predictive value (98-100%),
nd thus it was concluded that the principal usefulness of
his marker lies in the fact that advanced ﬁbrosis and cir-
hosis can be ruled out, depending on its serum level.16
icroﬁbrillar-associated protein 4
icroﬁbrillar-associated protein 4 is a collagen-binding pro-
ein that contains a ﬁbrinogen-like domain in its C-terminal
nd and an integrin-binding motif in the N-terminal end of
he molecule. It participates in the innate immune response
nd enables the free gaseous interchange in the lungs
hrough its association with the collagen region of surfac-
ant proteins (SP-A and SP-D). The N-terminal region of
he protein includes a residual cysteine and an Arg-Gly-Asp
RGD) sequence that is a cellular adhesion motif for var-
ous members of the integrin family.34 In a recent study,
icroﬁbrillar-associated protein 4 showed highly precise
iagnostic serum levels for predicting cirrhosis in a con-
rol group (healthy individuals) compared with a group of
CV patients (AUROC= 0.97, p < 0.0001) with a sensitivity of
1.6% and a speciﬁcity of 95.6%,35 as well as in stage F0
ompared with F4 (AUROC= 0.84, p < 0.0001), and in stages
0-F3 versus F4 (AUROC= 0.76, p < 0.0001).21,36 This protein
s also an ideal marker in serum (data to be published) among
he liver-speciﬁc proteins obtained from our experimental
odel of ﬁbrosis conducted on rats.
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Table 3 Serologic indices of the multicomponent tests.
Study Serologic test Sensitivity (%)a Speciﬁcity (%)a
APRI AST/platelets 89 75
PGA Prothrombin, GGT, apolipoprotein A1 91 81
PGAA Prothrombin times, GGT, apolipoprotein A1,
2-macroglobulin
66 72
Forns Age, platelets, GGT, cholesterol 94 51
FibroTest Age, sex, GGT, bilirubin, 2-macroglobulin,
apolipoprotein A1, haptoglobin
75 85
HepaScore Age, sex, bilirubin, GGT, hyaluronic acid,
2-macroglobulin
71 84
FIB-4 Platelets, ALT, AST, age 70 74
FibroIndex Platelets, AST, GGT 78 74
FibroMeter Platelets, AST, age, 2-macroglobulin,
prothrombin times, hyaluronic acid, urea
81 84
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: -glutamyl transferase.
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a Values correspond to comparisons made in F4 patients.
ndirect markers (multi-components)
irect and indirect markers can be used alone or combined
o produce composite scores. The calculation of such indices
an be relatively simple or can be based on complicated
ormulas (for example, Fibrotest/Fibrosure);21 the FibroTest
FT, patented by Biopredictive, Paris, France) was the ﬁrst
ulti-component test that combined the resulting data from
ifferent tests.23,37 Other indices have also been proposed, 4
f which are patented and commercial, and others are being
tudied. These indices are described in Table 3.
he PGA index
his index combines the measuring of the PT index and
-glutamyl transferase and apolipoprotein A1 levels. The
etermination of 2-macroglobulin was added later, result-
ng in PGAA and improved performance. In chronic liver
iseases, the PGA index is related to both inﬂammation and
brosis (p < 0.01, p < 0.05, respectively). However, in gen-
ral, its precision for detecting cirrhosis is relatively low
66-72%).19,38--40
PRI
PRI is the index resulting from the AST-platelet ratio and is
alculated as follows:
(AST/upper limit of the normal range∗) × 100
PLT(109/L)
* depends on the reference value of each laboratory.
APRI has been validated in groups of patients with HCV
nd as a substitute marker of signiﬁcant liver ﬁbrosis in
atients coinfected with HIV/HCV. It has recently been
mployed to determine advanced ﬁbrosis in patients with
IV;41 however, the result of a meta-analysis suggested that
he APRI can identify the hepatitis C-ﬁbrosis ratio with only
n
f
s
imoderate degree of precision (63.74%, p < 0.01) and with a
ensitivity and speciﬁcity of 89% and 75%, respectively.42,43
he Forns index
his index is based on 4 routine clinical variables: age,
latelet count, and cholesterol and -glutamyl transferase
evels. With this method, patients with mild ﬁbrosis (F0-F1)
an be differentiated from those with advanced ﬁbrosis (F2-
4), but it is less accurate for distinguishing patients with
rades between F2 and F4. The Forns index has been val-
dated in other cohorts as a prediction tool for anti-HCV
herapy response, with sensitivity and speciﬁcity values of
4% and 51%, respectively, and an AUROC that varies from
.81-0.86.36,44
epaScore
his index combines age and sex with serum concen-
rations of bilirubin, -glutamyl transferase, HA, and
2-macroglobulin with a score from 0 to 1. In 2 independent
tudies, one with 512 patients with chronic hepatitis C and
he other with 117 patients with hepatitis C, both untreated,
he HepaScore showed favorable predictive values for
dentifying signiﬁcant ﬁbrosis (AUROC= 0.81-0.85), severe
brosis (AUROC= 0.82-0.96), and cirrhosis (AUROC= 0.88-
.94). The values obtained varied from: 92% speciﬁcity and
7% sensitivity for signiﬁcant ﬁbrosis, between 81% and 95%
or severe ﬁbrosis, and 84% and 71% for cirrhosis. It is impor-
ant to point out that HepaScore can be automatized using
single analyzer.45,46
ibroTest and FibroSURE
hese are identical tests for evaluating ﬁbrosis grade and
ecroinﬂammatory activity. They are marketed under dif-
erent names in Europe and America. The FibroTest (FT)
core is obtained by accessing a license from a website and
ts calculation is based on the age of the patient, sex, and
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the concentration of serum haptoglobin, 2-macroglobulin,
apolipoprotein A1, -glutamyl transferase, and bilirubin.47
The score is arrived at with these data and is correlated
with the grade of liver damage. Due to the variability of the
assay components and the type of analyzers used, the FT
can only be carried out in validated laboratories. For the
purpose of validating the FT with respect to biopsy, the test
was applied to 2,472 untreated patients: 770 with chronic
hepatitis C, 723 with hepatitis B, 761 with nonalcoholic fatty
liver disease, and 218 with alcoholic liver disease. There was
a signiﬁcant parallelism among them with an intraclass cor-
relation = 0.961 (95% CI: 0.948 to 0.970) and 0.899 (95% CI:
0.135 to 0.969) for F4 and F0, respectively. This agreement
was maintained according to disease and sex. A faster pro-
gression of ﬁbrosis toward F4 (biopsy/FT) was observed in
men with nonalcoholic fatty liver disease (1.44/1.62) and
a slower one was observed for women (0.09/0.02).48 In a
prospective study (2008-2010), 194 patients with HBV under-
went liver biopsy, together with FT application and transient
elastography (TE), and it was determined that for predicting
signiﬁcant ﬁbrosis (F ≥ 2), severe ﬁbrosis (F ≥ 3), and cirrho-
sis (F4), the AUROC calculations of the FT were 0.903, 0.907,
and 0.866, respectively. According to the cut-off points, 123
patients (63.4%) were correctly classiﬁed with respect to
histologic ﬁbrosis. The best AUROCs were obtained by mul-
tiplying FT (TE× FT) and the results were 0.941, 0.931, and
0.929 for F ≥ 2, F ≥ 3, and F4, respectively.49 This marker’s
sensitivity and speciﬁcity for predicting cirrhosis were 75%
and 85%, respectively.
FibroMax
FibroMax is a system that groups 3 different tests together
for diagnosing ﬁbrosis (Fibro Test), steatosis (SteatoTest),
and nonalcoholic steatohepatitis (NASH Test). Having the
results of these 3 assays together on a single sheet provides
physicians with a simultaneous and complete estimate of the
hepatic lesion associated with nonalcoholic fatty liver dis-
ease, combining 10 markers, the patient’s age, sex, height
and weight, 2-macroglobulin, haptoglobin, apolipoprotein
A1, -glutamyl transferase, total bilirubin, ALT, AST, total
cholesterol, triglycerides, and glucose (fasting).50 There are
very few studies that have validated these tests together;
one analysis done in Cairo on 44 patients with HCV that
correlated histopathology and body mass index through the
FibroMax and liver biopsy, showed a signiﬁcant positive asso-
ciation between body mass index and the SteatoTest through
FibroMax, with an AUROC of 0.67, 100% sensitivity, and 99%
speciﬁcity.51
FibroMeter
The FibroMeter (FM) is a multicomponent assay that com-
bines patient age, platelet count, prothrombin index, AST,
2 macroglobulin, HA, and ureic nitrogen in blood. FM appli-
cability and performance were validated in the diagnosis of
different chronic liver diseases, including chronic HBV and
HCV, alcoholic liver disease, and nonalcoholic fatty liver dis-
ease. One important characteristic of FM is that it describes
the quantity of liver ﬁbrosis in percentage values of ﬁbrotic
tissue inside the liver. Another very signiﬁcant character-
istic is that it validates the results through a system that
detects erroneous values. FM has 2 main diagnostic aims:
m
e
e
ltages 193
o establish the stage of ﬁbrosis that corresponds to the
etavir histologic index and the quantity of ﬁbrosis related
o the morphometric determinations of the ﬁbrotic zone.21
he sensitivity and speciﬁcity for predicting cirrhosis are 81%
nd 84%, respectively.
iver hardness markers
hysicians regularly employ manual palpation to evaluate
ertain diseases. This method is limited to large, superﬁcial
tructures that in general are considerably more rigid that
he surrounding tissue. For years, research has been carried
ut on methods designed to visualize the mechanical prop-
rties of the tissues, and in contrast to palpation, they have
reater sensitivity and speciﬁcity.52
One of the recent methods utilized more frequently for
stimating liver ﬁbrosis in patients with chronic diseases is
he noninvasive liver stiffness measurement. However, there
s growing evidence that ﬁbrosis is not the only determining
actor in liver stiffness; in fact, inﬂammation, cholestasis,
nd congestion could also interfere with its measurement.53
In the methods for visualizing elasticity, there are 2 gen-
ral approaches for forming the image: 1) the creation of
mages that reﬂect the relative differences in tissue stiff-
ess (in other words, images of tension, such as TE) and 2)
arrying out reconstructions that are related to the displace-
ent response to the underlying tension, properties of the
aterials that make the creation of quantitative images of
he elasticity possible (for example, ARFI).54
ransient elastography
iver ﬁbrosis can also be represented by one-dimensional
ltrasound (1D) through TE that measures the propagation
elocity of the elastic wave by emitting a low frequency
--50Hz) vibration into the liver. This velocity, called elastic
odulus (expressed as E = 3pv2, in which v is the shear veloc-
ty and p is the tissue density) is directly related to tissue
tiffness.
The stiffer the tissue, the faster the shear wave is prop-
gated. TE measures the stiffness of the liver in a volume
hat approximates that of a 1 cm wide and 4 cm long cylin-
er, 25-65mm under the surface of the skin. The results are
xpressed in kilopascals (kPa) with a range of 2.5 to 75 kPa,
nd whose normal value is approximately 5 kPa.55 The stud-
es that support the use of TE for quantifying ﬁbrosis have
een carried out on patients with hepatitis C and conﬁrmed
n patients with hepatitis B. The test correctly classiﬁes cir-
hosis in a range from 85% to 94%, but not signiﬁcant ﬁbrosis
ith values ranging from 57% to 90%,56 as has been conﬁrmed
y meta-analyses (32 articles and 8 abstracts) whose sensi-
ivity and speciﬁcity values ﬂuctuate between 0.83 and 0.89
n patients with cirrhosis and 0.79 and 0.78 in patients with
igniﬁcant ﬁbrosis.57
TE is a reproducible noninvasive tool with satisfactory
nd reproducible accuracy for estimating liver ﬁbrosis and
teatosis. Unfortunately, measurements cannot always be
ade in obese patients and they can have higher results,
ven at the same stage of liver ﬁbrosis.58 It is important to
valuate liver steatosis, not only because nonalcoholic fatty
iver disease is a common hepatic disorder, but also because
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cirrhosis and its sensitivity and speciﬁcity values are 90%.
In a study conducted on 141 patients analyzed through94
teatosis frequently coexists with other chronic liver dis-
ases (HCV).59
A new physical parameter has recently been developed
or evaluating steatosis based on the properties of ultra-
ound signals. This controlled attenuation parameter is a
easurement of ultrasound attenuation (3.5MHz),60 a phys-
cal property of the propagation medium that corresponds to
he energy loss in the form of ultrasounds that travel through
he medium. In other words, the intensity of the emitted
ltrasounds exponentially decreases with depth. In a ret-
ospective study conducted on 115 patients with chronic
iver disease of mixed etiology, the controlled attenuation
as found to be effective in detecting low-grade steatosis
>10%).58
On the other hand, S and XL probes were developed to
ttend to different population groups (pediatric and obese).
he S probe achieves higher frequencies and shallower mea-
urements under the surface of the skin, which are adapted
o constitutionally small pediatric patients.61 The XL probe
eaches a lower frequency with a more sensitive transducer,
onger length, a broad vibration amplitude, and greater
epth under the skin surface. This probe is useful in obese
ubjects.62
The validation studies for this probe are few, but con-
istent. One of them includes 286 patients, in whom 92%
f the measurements with the XL probe were more reliable
han those with the M probe (80%).63 Another study con-
ucted on 193 patients with nonalcoholic fatty liver disease
roduced reasonable cut-off values for both: 78% for sensi-
ivity and speciﬁcity, a positive predictive value of 60%, and
negative predictive value of 89% in F3.64 Further studies
re needed to deﬁne the adequate cut-off point for XL probe
se in different etiologies.
udden acoustic radiation force impulses
he analysis of images obtained through sudden acoustic
adiation force impulses (ARFI) is a new technology for car-
ying out real time liver stiffness measurement. The use of a
tandard echographic probe provides two-dimensional (2D)
lastographic images through a ﬂexible measurement with
arying depth, allowing the examination of a speciﬁc area.
ARFI mechanically excites tissue using short-lasting
coustic impulses (--262sec) that propagate, creating dis-
lacing shear waves in the tissue that are located on a
icro scale. Compared with TE, the shear wave velocity
expressed in meters/sec) measures a very small region
10mm long and 6mm wide) that can be chosen by the
perator.52,54
The conventional diagnostic ultrasound images show
he differences in the acoustic properties of soft tissues,
hereas the ultrasound images based on elasticity repre-
ent the differences in their elastic properties (stiffness and
iscosity).
The advantage of the formation of images based on elas-
icity lies in the fact that many soft tissues can share a
imilar capacity for reﬂecting ultrasonic waves, but have
ifferent mechanical properties that can be employed to
learly visualize the normal anatomy and outline the patho-
ogic lesions.
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The elasticity imaging methods are based on the use of
coustic radiation force to transitorily deform the soft tis-
ue, measuring the dynamic displacement tissue response
hrough ultrasounds, using them to estimate the mechanical
roperties of the tissue.
Both the qualitative images and the quantitative mea-
urements of elasticity can be reconstructed from these
ata, providing complementary information about disease
rogression for both diagnostic and longitudinal follow-up
urposes.
Preliminary results indicate that the accuracy of ARFI is
imilar to that of elastography. Nevertheless, the majority of
tudies are based on small samples of heterogeneous popu-
ations and liver biopsy is not always used as a reference.65
agnetic resonance elastography
ver the last decade, there have been technological
dvances in the development of magnetic resonance (MR)
s a clinical application, focusing on the use of the physio-
ogic and biomechanical properties of human liver tissue for
mproving the detection of focal and diffuse pathologic con-
itions, reporting an excellent correlation between stiffness
nd liver ﬁbrosis.66
Recently, the technique of MR elastography for evaluat-
ng the stiffness of different types of tissue has also been
escribed. MR elastography uses a modiﬁed phase-contrast
echnique that is sensitive to the propagation characteris-
ics of the acoustic shear waves that are produced in the
rgan of interest.67
The technique can be implemented in a conventional MR
ystem with the addition of simple hardware and software. It
an be added to a MR examination of the upper abdomen by
lacing a pneumatic or electromechanical inducer in contact
ith the abdominal wall of the patient in the supine posi-
ion. The inducer generates mechanical wave propagation in
he liver at frequencies between 40 and 120Hz. The patient
eed only hold his or her breath for 10-15 seconds in order
or the images of the wave propagation to be formed in a
ransverse section of the abdomen.66,68,69
To capture the image of the waves that are propagated in
he liver, a contrast-phase MR sequence is used that employs
rogrammed movement gradients that synchronously vary
ith the applied vibrations, enabling the waves to be easily
isualized with amplitudes in the micra range.
Each elastographic acquisition provides an image of
he displacement caused by the propagated wave in the
edium. The wave images are then processed using an inver-
ion algorithm that is specially developed for generating
uantitative images that capture the stiffness of the tissue,
alled elastograms; when these are taken at the sites of
nterest in the organ, they provide signiﬁcant elasticity val-
es. The elasticity unit of measurement is the kPa, the same
s in ultrasound-based TE.66 It can very accurately diagnose
40double exam (MR elastography and APRI tests), ﬁbrosis
tage was evaluated and the results were compared. The
onclusion was that liver ﬁbrosis is staged more accurately
hrough MR elastography than with the APRI.70
dvan
a
e
t
t
3
i
b
s
t
m
h
d
i
t
e
o
b
c
t
l
h
t
t
o
s
b
o
e
d
d
m
o
t
t
a
V
E
v
u
o
c
i
M
p
b
p
pBiomarkers for liver ﬁbrosis: Advances, advantages and disa
Biomarker advantages and disadvantages
As with all diagnostic tests, biomarkers have advantages
and disadvantages that can tip the scale for their use as
a noninvasive diagnostic and follow-up method.
The obvious advantage of biomarkers over biopsy is
that their determination in samples is minimally invasive.
Biopsy requires local anesthesia or intravenous analgesia
and/or sedation with short-acting benzodiazepines followed
by puncture that involves tissue rupture with the possibility
of complications, which although infrequent, can be fatal.
That obvious advantage aside, the main quality of the
noninvasive method for the clinical prediction of ﬁbrosis
over biopsy, in addition to its easy applicability, inter-
laboratory reproducibility, and general availability (easy
distribution), is that these tests can evaluate the course of
the pathophysiologic functions and processes.
An example of this is a study that analyzed the associa-
tion between the serum levels of the ﬁbrosis markers with
the risk for clinical and histologic disease progression. It was
conducted on 462 patients infected with HCV that did not
respond to pegylated interferon and ribavirin. The evalu-
ation included an initial reference test and annual serum
assays of HA, the type III procollagen N-terminal peptide,
TIMP-1, and YKL-40. Pretreatment biopsies were taken and
all had follow-up at the 2nd and 4th year. The clinical results
included decomposition development data, hepatocellular
cancer, death, or an increase in the Child-Turcotte-Pugh
classiﬁcation ≥ 7.
The line of reference of HA, YKL-40, and TIMP-1 in
the levels combined with other laboratory parameters
was signiﬁcantly associated with the clinical results in 69
patients with disease progression of 15%, p < 0.0001. All
the baseline levels of the ﬁbrosis markers in serum were
signiﬁcantly associated with histologic ﬁbrosis progression
that developed in 70 of the 209 patients with cirrhosis
(33%, p < 0.0001). However, the HA and platelet counts were
better predictors of the histologic progression of ﬁbrosis
(AUROC= 0.663).71 Therefore, it was concluded that HA had
a predictive value for cirrhosis resulting from HCV infection
and its serum level correlated with the Child-Pugh score in
these patients.56
HA and PIIINP levels independently predict primary bil-
iary cirrhosis progression, whereas laminin values correlate
with the Child-Pugh levels of liver cirrhosis, regardless of
etiology. For their part, elevated levels of PIIINP and YKL-
40 are predictive for a shorter survival in patients with
alcohol-induced cirrhosis.23 In relation to ﬁbrosis grade,
the serum levels of YKL-40 determined through radioim-
munoassay in the serum of 129 patients showed a signiﬁcant
increase in this molecule (p < 0.001) in individuals with mod-
erate (466 ug/L) to severe (676 ug/L) ﬁbrosis. YKL-40 was
also increased (p = 0.018) in subjects with mild ﬁbrosis (270
ug/L).23
A retrospective French study of 1,457 patients with HCV
compared the capacity of different noninvasive methods (FT,
APRI, FIB-4, and TE) to predict the grade of survival and
death related to liver damage. The FT results produced high
predictive values for a period of up to 5 years, and they did
not vary after being adjusted based on treatment response,
patient age, or the estimated necroinﬂammatory grades.53
In general terms, the use of these noninvasive methods is
c
c
m
otages 195
n alternative to the use of traditionally accepted biopsy,
specially in the European countries.
Currently, the following are among the main disadvan-
ages of biomarkers: 1) none of them is liver-speciﬁc, 2)
heir results can be inﬂuenced by comorbid conditions, and
) they require critical interpretation.
The FibroTest and HepaScore produce false positives
n patients with Gilbert’s syndrome and with hyper-
ilirubinemia due to the presence of hemolysis in the
erum.72
Likewise, acute hepatitis can produce false positives in
he APRI tests, Forns index, or FibroMeter, because they all
easure the levels of aminotransferases and these are also
igher in non-ﬁbrosing liver diseases.
On the other hand, the serum levels of the marker
epend on the level of elimination of the molecule, which
s inﬂuenced by hepatic endothelial cell dysfunction and
he deterioration of biliary or renal excretion. These lev-
ls reﬂect not only the ECM deposit, but also the amount
f hepatic matrix turnover and they have the tendency to
e higher when there is great inﬂammatory activity. As a
onsequence, the matrix deposit may not be detected when
here is minimal inﬂammation.23
Another disadvantage is that biomarker evaluation is
imited to a speciﬁc pathologic condition (for example, alco-
olic liver disease) and its performance is compared with
hat of one or more panels, therefore it is difﬁcult to know
he exact contribution of a recently described marker.73
At present we can say that one of the main disadvantages
bserved in these types of tests is the discordance between
ensitivity and speciﬁcity, which so far has made it impossi-
le to choose one with unerring results for any type or grade
f ﬁbrotic disease.
The sensitivity or speciﬁcity variations should be
xpected every time some characteristic of the patient or
isease inﬂuences the results of the test, due to a pre-
ictable physiologic or biologic phenomenon.74,75
Finally, another of the big disadvantages is that the
ajority of these markers can only detect either very early
r advanced stages of disease, with a clear inability to dis-
inguish the intermediate stages.
In reference to the physical methods, we can say that
he main advantage of ARFI is its easy implementation into
modiﬁed commercial ultrasound machine (Acuson 2000
irtual Touch Tissue Quantiﬁcation; Siemens Healthcare,
rlangen, Germany). Nevertheless, unlike TE values, ARFI
alues have a narrow margin (0.5 to 4.4 m/sec). This partic-
larity limits the cut-off values for deciding the classiﬁcation
f the patients.19,21
In theory, the advantages of MR elastography include its
apacity to analyze almost the entire liver and its applicabil-
ty in patients presenting with obesity or ascites. However,
R elastography cannot be carried out in the livers of
atients with iron overload, due to the limitations caused
y signal-noise. It is also very expensive and requires a long
eriod of routine practice.66
On the other hand, TE has the advantage of being a short
rocedure (< 5min) that gives immediate results. The pro-
edure is very easy to learn, but accurate results require:
areful interpretation, a success rate (the ratio of valid
easurements to the total number of measurements) of
ver 60%, and an interquartile range (IQR) that reﬂects the
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invasive tests for diagnosing signiﬁcant ﬁbrosis (F > 2) cannot96
ariations between measurements under 30% of the value of
he median (IQR/M, 30%).76
TE is not recommended in patients presenting with obe-
ity and ascites because these conditions make it difﬁcult
o obtain good results. Abnormalities of tissue with edema,
nﬂammation due to extra-hepatic cholestasis, or congestion
ave also been observed to interfere with the measure-
ent of liver stiffness, regardless of ﬁbrosis; the inﬂuence
f steatosis is still a subject of debate.77
The only technology that currently competes with ultra-
ound elastography is MR elastography, because it is not
imited by the presence of bone or gas and is sensitive
o 3-dimensional movement; it has high velocity volume
cquisition, can be performed by relatively inexperienced
ractitioners, and result interpretation is very simple.78
Ultrasound evaluation of soft tissue tension and elasticity
s generally more competitive than MR assessment, there is
asier access to a scanner for patients and practitioners, and
he general cost per study is much lower.
dvances and perspectives
he search for new markers produced a wide variety of
andidates, but their numbers decreased as they were
eticulously evaluated in order to meet the necessary
equirements for this type of test. In contrast to existing
oninvasive predictor panels, the number of samples and
ontrols for marker validation is an important technical
hallenge, as is estimating the relative value of the novel
iological markers.
The performance of each biomarker is compared with
he beneﬁt or beneﬁts of one or more panels and its eval-
ation is limited to one pathologic condition (for example,
lcoholic liver disease). Therefore the exact contribution of
ach newly described biomarker is difﬁcult to determine.73
The appearance of new technologies such as proteomics
hat evaluates patterns of proteins or glycoproteins through
ass spectroscopy using serum samples has shown limited
pplicability because it is unable to distinguish the etiology
f pathologies that are not liver diseases.
For example, in 2004 Callewaert et al. developed a study
ased on the presence of total N-glycosylated proteins (Gly-
oCirrhoTest and GlycoFibro Test) with the serum of patients
resenting with chronic liver disease. The attempt to dis-
inguish cirrhosis through the combination of the 2 tests
roduced a sensitivity of 79% and a speciﬁcity of 86%.79 On
he other hand, the same modiﬁcations in the serum proteins
glycosylation) continuously appear in all liver diseases,80
hus it is necessary to broaden prospective studies in order
o determine the clinical application of these techniques.
astLec-Hepa is an accurate system that can evaluate the
reatment of patients with HCV; it is based on an immunoas-
ay that detects hyperglycosylation of the Mac-2 binding
rotein (M2BP) and is sensitive and quantitative for cal-
ulating the therapeutic effects of -PEG-interferon and
ibavirin within a short post-therapeutic interval. Fibro-
is progression is equivalent to --0.30 stages per year,
n patients with sustained viral response and 0.01 stages
er year in patients with recurrence or non-responders.
astLec-Hepa is currently available for indirectly evaluat-
ng the existing correlation between the therapy and the
s
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lycosylation quantiﬁcation of this protein activated during
bro-proliferative diseases, even though it was not speciﬁ-
ally developed for that purpose.81
Phosphoproteomics can improve the understanding of
iver ﬁbrosis pathogeny, using the phosphorylated proﬁles
f the proteins that participate in the signaling pathways
f this process, as demonstrated by Younossi et al.82 Their
esults suggest that the phosphoprotein biomarkers could
otentially be used in a clinical environment for identify-
ng patients presenting with nonalcoholic steatohepatitis;
t provides information about the metabolic pathways that
ay be involved in the pathogeny of the disease.
In summary, despite the emergence of new technologies,
he acquired protein patterns, whether obtained by glyco-
ylation or fucosylation, have problems differentiating both
he stage and speciﬁcity of ﬁbrosis.
Moreover, due to the difﬁculty in evaluating each of these
arkers, their statistical comparison has been recurred
o, as reported in the most recent analysis of 172 studies
valuating the diagnostic accuracy of ﬁbrosis and cirrhosis
arkers. The results for ﬁbrosis were: the probability quo-
ients of cut-off points of 5-10 had positive medians and
UROC (0.71 to 0.86) for platelet count, APRI, FibroIndex,
ibroTest, and the Forns index; and for cirrhosis they were:
UROC (0.80 a 0.91) for platelet count, APRI, and HepaS-
ore. The authors state that the main difﬁculty for carrying
ut these types of studies is the lack of methodological
escription and the limited interpretation of the liver biopsy,
s well as insufﬁcient inclusion methods.83
onclusions and discussion
he successful management of chronic liver disease treat-
ent depends on the correct staging of ﬁbrosis. Noninvasive
eproducible tests are necessary for providing the means for
isease diagnosis and follow-up, and therapeutic response.
he process of ﬁbrogenesis is a common response of the
iver when there is a chronic lesion produced by a vari-
ty of aggressions as part of disease development,3 and
as made the adequate search for speciﬁc biomarkers
ifﬁcult, becoming a challenge in translational hepatol-
gy.
A series of noninvasive techniques are being developed,
anging from serum assays to image acquisition. FibroScan
nd elastometry are among the most successful noninva-
ive methods, as well as those based on serologic assays
uch as APRI and FibroTest.19 There are other tests that
re promising, but they have not yet been validated. In
ddition to including a large number of patients, val-
dation should also encompass other important factors,
uch as body mass index, ethnicity, and liver disease
tiology.73
It is important to point out that the majority of non-
nvasive tests are not able to accurately differentiate the
arly stages of ﬁbrosis. In fact, most of these tests mainly
dentify cirrhosis with minimal ﬁbrosis. At present the non-ubstitute biopsy. Therefore, the present usefulness of non-
nvasive diagnosis is still limited because it only allows the
hysician to reduce the population of patients that are can-
idates for liver biopsy.
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